Current Management and Potential Role of HIF-PHIs

CME

Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: November 16, 2022

Expiration: November 16, 2023

Erin Michos
Erin Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Matthew Weir
Matthew Weir, MD

Pretest

Progress
1 2
Course Completed
1.

How confident are you in your ability to discuss the etiology and management of anemia in your patients with CKD who develop anemia?

2.

Your patient, George, has an eGFR of 55 mL/min/1.73 m2 and a Hgb of 9.9 g/dL. This is concerning because patients with CKD and anemia have an increased risk of all-cause mortality compared to those without anemia, with a hazard ratio of:

3.

Which of the following contributes to the development of anemia in CKD? 

4.

Which of the following is a consideration when selecting a therapy of anemia in CKD? 

5.

The mechanism of action of Hypoxia-Inducible Factor (HIF)-Proline Hydroxylase Inhibitor (PHI) agents is based on which of the following?